Skip to content

Therakos Development Limited

Country not established FDA

Devices
1
Registrations
FDA
FDA recalls
11 ongoing

At a glance

Counted by deviCERTS from registry records

Market reach

United States
FDA establishment, FDA recalls

What Therakos Development Limited makes

Therakos Development Limited manufactures the UVAR XTS Procedural Kit, a device designed for extracorporeal photopheresis (ECP) therapy. This system is used to treat autoimmune and inflammatory skin conditions by exposing a patient’s white blood cells to ultraviolet light and reintroducing them into the body. The kit includes components necessary for the ECP procedure, including collection and processing bags, UV exposure chambers, and associated accessories.

The UVAR XTS Procedural Kit is classified as a Class III medical device under FDA regulations and requires Premarket Approval (PMA). It is listed in the FDA’s device registry, adhering to stringent requirements for high-risk devices. The company is based in the United States.

AI-generated from registry data, 26 Oct 2026. Not verified by deviCERTS or the manufacturer.

Catalogue1

Newest first, rows 1-1 of 1

  • Uvar Xts Procedural Kit Ref P860003 Open recall

    Active Regimes: PMA Registry: PMA Class:III

FDA recalls1

Recalls are matched to the firm by name. FDA recall data as of 22 Oct 2026.

FDA recall records list 1 recall initiated by Therakos Development Limited, initiated on 2025-05-16. By recorded status: 1 ongoing. The reasons filed fall into these groups: labeling or instructions for use. A recall is often a precaution started by the manufacturer, and a count of records is not a verdict on a company.

Generated automatically from FDA recall records, as a summary of the records listed below. It describes what the records state and is not an assessment of this manufacturer.

Recalls initiated per year

  • 2017 0
  • 2018 0
  • 2019 0
  • 2020 0
  • 2021 0
  • 2022 0
  • 2023 0
  • 2024 0
  • 2025 1
  • 2026 0
  • 2025

    • 16 May 2025 Z-1822-2026 Class II Ongoing Increased difficulty in installing the centrifuge bowl onto the centrifuge bowl holder. Improper installation may cause the centrifuge bowl to dislodge, resulting in a broken bowl during the prime cycle or treatment phase, leading to a delay in patient treatment and blood loss. Distribution: US Nationwide distribution. Submission number: P860003

FDA establishments1

Registered with the FDA under this company group, matched by name.

  • Therakos Development Limited Blanchardstown Dublin(County) · IE FEI 3036773437

Frequently asked questions

How many devices does Therakos Development Limited have in the registry?

The registry currently lists 1 device for Therakos Development Limited. Devices recorded under merged duplicate company entries are counted once.

Which registries list Therakos Development Limited's devices?

Among its 1 most recently registered device, Therakos Development Limited has devices listed in FDA PMA (1 device).

What risk classes do Therakos Development Limited's devices fall under?

Among its 1 most recently registered device, the classes recorded for Therakos Development Limited's devices are Class III. Each device page shows its own class and authorisation.

Are there FDA recall records for Therakos Development Limited?

FDA recall records list 1 recall initiated by Therakos Development Limited, the most recent initiated on 16 May 2025. 1 of them is recorded as ongoing. A recall is often a precaution started by the manufacturer; the records say nothing about the company's overall record.

What are the newest devices from Therakos Development Limited in the registry?

The most recently registered devices listed for Therakos Development Limited include UVAR XTS PROCEDURAL KIT.

Which FDA establishments are linked to Therakos Development Limited?

1 FDA establishment is linked to Therakos Development Limited in the registry; they are listed on the company page.

Generated automatically from registry data and not verified by a human reviewer.